28393896|t|Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence
28393896|a|Ibudilast, a nonselective phosphodiesterase inhibitor, is used clinically in Asia for the treatment of asthma and poststroke dizziness. Recent preclinical studies have suggested that it also inhibits glial cell activation in rodents, and may alter opioid - mediated effects, including analgesia and withdrawal symptoms. The effects of ibudilast on the abuse potential of opioids in humans are largely unknown. The present study was designed to examine the influence of ibudilast on subjective (including drug craving), reinforcing, and analgesic effects of oxycodone in human volunteers diagnosed with opioid dependence (equivalent to moderate-severe opioid use disorder). Non-treatment-seeking opioid-dependent male volunteers (n=11) underwent an in-patient detoxification with morphine, followed by maintenance on placebo (0 mg b.i.d.) and active ibudilast (50 mg b.i.d.). Under each maintenance dose, six experimental sample and choice sessions were completed involving oral oxycodone administration (0, 15, and 30 mg/70 kg, p.o.). Subjective effects of oxycodone and drug craving were measured with visual analog scales (VAS) and a Drug Effects Questionnaire. The cold pressor test was used to produce pain, and a modified progressive-ratio choice procedure was used to measure the reinforcing effects of oxycodone. Under the active ibudilast condition compared with the placebo condition, ratings of drug liking following 15 mg of oxycodone were decreased significantly. The mean drug breakpoint value was also significantly lower in the active vs the placebo ibudilast condition under the 15 mg oxycodone condition, but not significantly lower under the 30 mg oxycodone condition. Heroin craving was significantly reduced under active ibudilast vs placebo, and similar effects were observed for tobacco and cocaine craving. Furthermore, mean subjective ratings of pain were lower in the active ibudilast condition. Our data suggest that ibudilast may be useful for treating opioid use disorders and it may enhance the analgesic effects of oxycodone .Neuropsychopharmacology advance online publication, 10 May 2017; doi:10.1038/npp.2017.70.
28393896	11	20	Ibudilast	T109,T121	C0123047
28393896	28	38	Subjective	T080	C0439655
28393896	40	51	Reinforcing	T058	C2712291
28393896	57	74	Analgesic Effects	T033	C0948482
28393896	78	87	Oxycodone	T109,T121	C0030049
28393896	100	110	Detoxified	T061	C0150543
28393896	111	117	Adults	T100	C0001675
28393896	123	140	Opioid Dependence	T048	C0524662
28393896	141	150	Ibudilast	T109,T121	C0123047
28393896	167	194	phosphodiesterase inhibitor	T121	C0031638
28393896	204	214	clinically	T080	C0205210
28393896	218	222	Asia	T083	C0003980
28393896	231	240	treatment	T061	C0087111
28393896	244	250	asthma	T047	C0004096
28393896	255	275	poststroke dizziness	T184	C0012833
28393896	284	303	preclinical studies	T062	C1709631
28393896	341	351	glial cell	T025	C0027836
28393896	352	362	activation	T043	C2259058
28393896	366	373	rodents	T015	C0035804
28393896	389	395	opioid	T109,T121,T131	C0242402
28393896	398	414	mediated effects	T169	C0728866
28393896	426	435	analgesia	T061	C0002766
28393896	440	459	withdrawal symptoms	T184	C0087169
28393896	476	485	ibudilast	T109,T121	C0123047
28393896	493	508	abuse potential	T080	C0237444
28393896	512	519	opioids	T109,T121,T131	C0242402
28393896	523	529	humans	T016	C0086418
28393896	585	592	examine	T033	C0332128
28393896	610	619	ibudilast	T109,T121	C0123047
28393896	623	633	subjective	T080	C0439655
28393896	645	657	drug craving	T033	C0556446
28393896	660	671	reinforcing	T058	C2712291
28393896	677	694	analgesic effects	T033	C0948482
28393896	698	707	oxycodone	T109,T121	C0030049
28393896	711	716	human	T016	C0086418
28393896	717	727	volunteers	T055	C0439656
28393896	728	737	diagnosed	T033	C0011900
28393896	743	760	opioid dependence	T048	C0524662
28393896	792	798	opioid	T109,T121,T131	C0242402
28393896	799	811	use disorder	T048	C0013222
28393896	836	852	opioid-dependent	T048	C0524662
28393896	853	857	male	T098	C0025266
28393896	858	868	volunteers	T055	C0439656
28393896	889	899	in-patient	T101	C0030705
28393896	900	914	detoxification	T061	C0150543
28393896	920	928	morphine	T109,T121	C0026549
28393896	942	953	maintenance	T052	C0024501
28393896	957	964	placebo	T122	C1696465
28393896	983	989	active	T169	C0205177
28393896	990	999	ibudilast	T109,T121	C0123047
28393896	1027	1043	maintenance dose	T081	C3714445
28393896	1049	1061	experimental	T062	C0681814
28393896	1114	1118	oral	T082	C0442027
28393896	1119	1128	oxycodone	T109,T121	C0030049
28393896	1129	1143	administration	T061	C0001563
28393896	1176	1194	Subjective effects	T080	C0439655
28393896	1198	1207	oxycodone	T109,T121	C0030049
28393896	1212	1224	drug craving	T033	C0556446
28393896	1244	1264	visual analog scales	T060	C3536884
28393896	1266	1269	VAS	T060	C3536884
28393896	1277	1303	Drug Effects Questionnaire	T170	C0034394
28393896	1309	1326	cold pressor test	T060	C0444689
28393896	1347	1351	pain	T184	C0030193
28393896	1368	1402	progressive-ratio choice procedure	T059	C0022885
28393896	1427	1446	reinforcing effects	T058	C2712291
28393896	1450	1459	oxycodone	T109,T121	C0030049
28393896	1471	1477	active	T169	C0205177
28393896	1478	1487	ibudilast	T109,T121	C0123047
28393896	1516	1523	placebo	T122	C1696465
28393896	1535	1542	ratings	T081	C0392762
28393896	1546	1550	drug	T121	C0013227
28393896	1551	1557	liking	T041	C0870814
28393896	1577	1586	oxycodone	T109,T121	C0030049
28393896	1592	1601	decreased	T081	C0205216
28393896	1602	1615	significantly	T078	C0750502
28393896	1621	1647	mean drug breakpoint value	T081	C1522609
28393896	1657	1670	significantly	T078	C0750502
28393896	1671	1676	lower	T080	C0205251
28393896	1684	1690	active	T169	C0205177
28393896	1698	1705	placebo	T122	C1696465
28393896	1706	1715	ibudilast	T109,T121	C0123047
28393896	1742	1751	oxycodone	T109,T121	C0030049
28393896	1771	1784	significantly	T078	C0750502
28393896	1785	1790	lower	T080	C0205251
28393896	1807	1816	oxycodone	T109,T121	C0030049
28393896	1828	1842	Heroin craving	T033	C0556446
28393896	1847	1860	significantly	T078	C0750502
28393896	1861	1868	reduced	T080	C0392756
28393896	1875	1881	active	T169	C0205177
28393896	1882	1891	ibudilast	T109,T121	C0123047
28393896	1895	1902	placebo	T122	C1696465
28393896	1942	1949	tobacco	T033	C0556446
28393896	1954	1969	cocaine craving	T184	C2138383
28393896	1984	2007	mean subjective ratings	T081	C0392762
28393896	2011	2015	pain	T184	C0030193
28393896	2021	2026	lower	T080	C0205251
28393896	2034	2040	active	T169	C0205177
28393896	2041	2050	ibudilast	T109,T121	C0123047
28393896	2066	2070	data	T078	C1511726
28393896	2084	2093	ibudilast	T109,T121	C0123047
28393896	2112	2120	treating	T061	C0087111
28393896	2121	2127	opioid	T109,T121,T131	C0242402
28393896	2128	2141	use disorders	T048	C0013222
28393896	2165	2182	analgesic effects	T033	C0948482
28393896	2186	2195	oxycodone	T109,T121	C0030049